Patent ID: 8980547
Filing Date: 2015-03-17
Classification: A61K,A61P,C12N

Abstract:
1. A method for reducing the formation of fibrils of tau protein or for disaggregating pre-formed fibrils of tau protein in a patient, comprising administering to the patient in need thereof a filamentous bacteriophage in an amount effective to achieve such reduction or disaggregation, wherein: the patient is not suffering from Alzheimer's Disease, including early onset Alzheimer's disease, late onset Alzheimer's disease, presymptomatic Alzheimer's disease; SAA amyloidosis; hereditary Icelandic syndrome; senility; multiple myeloma; kuru; Creutzfeldt-Jakob disease (CJD); Gerstmann-Straussler-Scheinker disease (GSS); other prion diseases, fatal familial insomnia (FFI) or Parkinson's Disease; and the filamentous bacteriophage is a filamentous bacteriophage selected from the group consisting of M13, f1 and fd bacteriophage, and mixtures thereof and does not display (i) a mammalian cell internalization signal, (ii) a β-amyloid antigen or an antibody to β-amyloid, or (iii) a tau protein antigen or an antibody to tau protein.